{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:47:40Z","timestamp":1791244060553,"version":"4.1.0"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the risk of rheumatic disease flare and adverse effects in patients with preexisting rheumatic disease who were receiving immune checkpoint inhibitor (<jats:styled-content style=\"fixed-case\">ICI<\/jats:styled-content>) therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective medical record review was performed to identify all patients who received <jats:styled-content style=\"fixed-case\">ICI<\/jats:styled-content> therapy at Mayo Clinic in Rochester, Minnesota between 2011 and 2016 (~700 patients). Those with a preexisting rheumatic disease were identified using specific diagnostic codes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen patients were identified (81% female, median age 68.5 years). The most common rheumatic diseases were rheumatoid arthritis (n = 5), polymyalgia rheumatica (n = 5), Sj\u00f6gren's syndrome (n = 2), and systemic lupus erythematosus (n = 2). Seven patients were receiving immunosuppressive therapy or glucocorticoids for their rheumatic disease at the time of initiation of the <jats:styled-content style=\"fixed-case\">ICI<\/jats:styled-content>. The primary malignancies were melanoma (n = 10), pulmonary (n = 4), or hematologic (n = 2). In most cases, <jats:styled-content style=\"fixed-case\">ICI<\/jats:styled-content>s were offered only after failure of several other therapies. Immune\u2010related adverse effects (<jats:styled-content style=\"fixed-case\">IRAE<\/jats:styled-content>s) occurred in 6 patients, and all were treated successfully with glucocorticoids and discontinuation of the <jats:styled-content style=\"fixed-case\">ICI<\/jats:styled-content> therapy. There were no significant differences in time from cancer diagnosis to immunotherapy, duration of immunotherapy, age, or sex between the patients with and those without <jats:styled-content style=\"fixed-case\">IRAE<\/jats:styled-content>s.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To our knowledge, this represents the largest single\u2010center cohort of patients with rheumatic diseases who were exposed to modern cancer immunotherapy. Only a minority of these patients experienced a flare of their preexisting rheumatic disease or any other <jats:styled-content style=\"fixed-case\">IRAE<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.40397","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:03:05Z","timestamp":1516752185000},"page":"356-360","source":"Crossref","is-referenced-by-count":94,"title":["Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience"],"prefix":"10.1002","volume":"70","author":[{"given":"Michael D.","family":"Richter","sequence":"first","affiliation":[{"name":"Mayo School of Graduate Medical Education Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Pinkston","sequence":"additional","affiliation":[{"name":"Mayo Clinic Jacksonville Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Kottschade","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi D.","family":"Finnes","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jacksonville, Florida and Mayo Clinic College of Medicine Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Thanarajasingam","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.131"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0117"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27969"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.4368"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.038"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw443"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw056"},{"key":"e_1_2_6_10_1","volume-title":"Common terminology criteria for adverse events (CTCAE)","author":"National Cancer Institute","year":"2009"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.09.007"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2017.01.004"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0133"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1136"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0081-1"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0193"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40397","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:46:40Z","timestamp":1759945600000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/art.40397"],"URL":"https:\/\/doi.org\/10.1002\/art.40397","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]}}}